Rodrigo Fresco

1.9k total citations · 1 hit paper
36 papers, 657 citations indexed

About

Rodrigo Fresco is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Rodrigo Fresco has authored 36 papers receiving a total of 657 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 11 papers in Cancer Research. Recurrent topics in Rodrigo Fresco's work include Breast Cancer Treatment Studies (10 papers), HER2/EGFR in Cancer Research (9 papers) and Advanced Breast Cancer Therapies (7 papers). Rodrigo Fresco is often cited by papers focused on Breast Cancer Treatment Studies (10 papers), HER2/EGFR in Cancer Research (9 papers) and Advanced Breast Cancer Therapies (7 papers). Rodrigo Fresco collaborates with scholars based in United States, Canada and France. Rodrigo Fresco's co-authors include Dennis J. Slamon, Chiun‐Sheng Huang, Miguel Martín, Sara A. Hurvitz, Daniil Stroyakovskiy, Vicente Valero, Nadia Harbeck, Hans‐Joachim Helms, Kyung Hae Jung and Alastair M. Thompson and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Rodrigo Fresco

32 papers receiving 653 citations

Hit Papers

Neoadjuvant trastuzumab, pertuzumab, and chemotherapy ver... 2017 2026 2020 2023 2017 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
    2017 337 citations Sara A. Hurvitz, Miguel Martín et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rodrigo Fresco United States 10 457 263 164 155 68 36 657
Yueyao Du China 17 255 0.6× 247 0.9× 115 0.7× 71 0.5× 240 3.5× 36 557
Tanja Stüber Germany 11 315 0.7× 116 0.4× 58 0.4× 57 0.4× 162 2.4× 23 639
Francine Hébert United States 15 251 0.5× 89 0.3× 118 0.7× 43 0.3× 185 2.7× 18 632
Eric Burton United States 14 186 0.4× 148 0.6× 205 1.3× 91 0.6× 207 3.0× 41 784
Anna Sutela Finland 15 112 0.2× 203 0.8× 68 0.4× 216 1.4× 89 1.3× 36 791
David C. Qian United States 10 202 0.4× 81 0.3× 93 0.6× 53 0.3× 106 1.6× 40 487
Nikolaos Pissimissis Greece 15 211 0.5× 157 0.6× 91 0.6× 22 0.1× 248 3.6× 19 597
Matthew G. Field United States 19 427 0.9× 121 0.5× 89 0.5× 274 1.8× 607 8.9× 41 1.5k
Prodipto Pal Canada 17 248 0.5× 166 0.6× 388 2.4× 43 0.3× 306 4.5× 49 956
Daniel G. Todd United States 8 257 0.6× 104 0.4× 193 1.2× 117 0.8× 291 4.3× 9 613

Countries citing papers authored by Rodrigo Fresco

Since Specialization
Citations

This map shows the geographic impact of Rodrigo Fresco's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rodrigo Fresco with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rodrigo Fresco more than expected).

Fields of papers citing papers by Rodrigo Fresco

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rodrigo Fresco. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rodrigo Fresco. The network helps show where Rodrigo Fresco may publish in the future.

Co-authorship network of co-authors of Rodrigo Fresco

This figure shows the co-authorship network connecting the top 25 collaborators of Rodrigo Fresco. A scholar is included among the top collaborators of Rodrigo Fresco based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rodrigo Fresco. Rodrigo Fresco is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fasching, Peter A., Dennis J. Slamon, Zbigniew Nowecki, et al.. (2025). Health-Related Quality of Life in Patients with HR+/HER2− Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial. Clinical Cancer Research. 31(9). 1625–1635. 2 indexed citations
2.
Yardley, Denise A., Michael Untch, Carlos H. Barrios, et al.. (2024). Baseline (BL) characteristics and efficacy endpoints for patients (pts) with node-negative (N0) HR+/HER2− early breast cancer (EBC): NATALEE trial.. Journal of Clinical Oncology. 42(16_suppl). 512–512. 3 indexed citations
3.
4.
5.
Slamon, Dennis J., Daniil Stroyakovskiy, Denise A. Yardley, et al.. (2023). Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial.. Journal of Clinical Oncology. 41(17_suppl). LBA500–LBA500. 82 indexed citations
6.
Spera, Gonzalo, et al.. (2019). Intensive Imaging Surveillance of Survivors of Breast Cancer May Increase Risk of Radiation-induced Malignancy. Clinical Breast Cancer. 19(3). e468–e474. 2 indexed citations
7.
Spera, Gonzalo, Rodrigo Fresco, Hoki Fung, et al.. (2017). Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE/TRIO-012 study. Annals of Oncology. 28(8). 1836–1841. 55 indexed citations
8.
Hurvitz, Sara A., Miguel Martín, W. Fraser Symmans, et al.. (2017). Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. The Lancet Oncology. 19(1). 115–126. 337 indexed citations breakdown →
9.
Damaraju, Sambasivarao, Karen A. Gelmon, José Á. García-Sáenz, et al.. (2016). Abstract P1-13-03: Genome wide association study (GWAS) of genetic variants associated with docetaxel toxicity in the ROSE/TRIO-012 trial. Cancer Research. 76(4_Supplement). P1–13. 1 indexed citations
10.
Barquet, Antonio, et al.. (2016). EPIDEMIOLOGY AND TREATMENT OF MONTEGGIA LESION IN ADULTS: SERIES OF 44 CASES. Acta Ortopédica Brasileira. 24(1). 48–51. 19 indexed citations
11.
Mackey, John R., Oleg Lipatov, Miguel Martín, et al.. (2015). Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial.. Journal of Clinical Oncology. 33(15_suppl). 547–547. 1 indexed citations
12.
Delgado, Lucı́a, et al.. (2012). Análisis de sobrevida según perfil biológico de pacientes uruguayas con cáncer de mama. SHILAP Revista de lepidopterología.
13.
Delgado, Lucı́a, et al.. (2010). Expresión tumoral de HER-2, receptores de estrógenos y de progesterona y su relación con características clínico-patológicas en pacientes uruguayas con cáncer de mama. SHILAP Revista de lepidopterología. 1 indexed citations
14.
Delgado, Lucı́a, et al.. (2010). BRCA1 and BRCA2 germline mutations in Uruguayan breast and breast–ovarian cancer families. Identification of novel mutations and unclassified variants. Breast Cancer Research and Treatment. 128(1). 211–218. 20 indexed citations
15.
Valle, Adriana Della, et al.. (2005). Frequency of hereditary non-polyposis colorectal cancer among Uruguayan patients with colorectal cancer. Clinical Genetics. 68(1). 80–87. 11 indexed citations
16.
Fresco, Rodrigo, et al.. (2004). Recomendaciones para la prevención y el tratamiento de náuseas y vómitos inducidos por quimioterapia. SHILAP Revista de lepidopterología. 20(2). 120–129.
17.
Fresco, Rodrigo, et al.. (2003). Synchronous Presentation of an Askin Tumor and a Plasmacytoma in an Adult Patient. Tumori Journal. 89(3). 324–327. 2 indexed citations
18.
Fresco, Rodrigo, et al.. (1971). Névrite optique rétro-bulbaire au cours d'un syndrome de Guillain-Barré.. 43(5). 3 indexed citations
19.
Fresco, Rodrigo, et al.. (1971). [Kleine-Levin syndrome (recurrent hypersomnia of male adolescents].. PubMed. 1(5). 625–68. 9 indexed citations
20.
Fresco, Rodrigo, et al.. (1970). [2 cases of Kleine-Levin syndrome].. PubMed. Suppl:55–9. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yueyao Du Breakdown of academic impact, for papers by Tanja Stüber Breakdown of academic impact, for papers by Francine Hébert Breakdown of academic impact, for papers by Eric Burton Breakdown of academic impact, for papers by Anna Sutela Breakdown of academic impact, for papers by David C. Qian Breakdown of academic impact, for papers by Nikolaos Pissimissis Breakdown of academic impact, for papers by Matthew G. Field Breakdown of academic impact, for papers by Prodipto Pal Breakdown of academic impact, for papers by Daniel G. Todd
Rankless by CCL
2026